These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20216907)

  • 1. Pharmacogenetics of adverse effects due to antiretroviral drugs.
    Vidal F; Gutiérrez F; Gutiérrez M; Olona M; Sánchez V; Mateo G; Peraire J; Viladés C; Veloso S; López-Dupla M; Domingo P
    AIDS Rev; 2010; 12(1):15-30. PubMed ID: 20216907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.
    Veloso S; Peraire J; Viladés C; López-Dupla M; Escoté X; Olona M; Garcia-Pardo G; Gómez-Bertomeu F; Soriano A; Sirvent JJ; Vidal F
    Curr Pharm Des; 2010 Oct; 16(30):3379-89. PubMed ID: 20687887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
    Cressey TR; Lallemant M
    Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and the potential for the individualization of antiretroviral therapy.
    Phillips EJ; Mallal SA
    Curr Opin Infect Dis; 2008 Feb; 21(1):16-24. PubMed ID: 18192781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of antiretroviral therapy in patients with HIV/AIDS].
    Cholewińska G
    Przegl Epidemiol; 2008; 62(1):149-54. PubMed ID: 18536238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.
    Kotb R; Vincent I; Dulioust A; Peretti D; Taburet AM; Delfraissy JF; Goujard C
    Eur J Haematol; 2006 Mar; 76(3):269-71. PubMed ID: 16451402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicities of antiretroviral therapy in children.
    Nwaobasi E; Oleske JM
    AIDS Read; 2006 Oct; 16(10):537-40, 544-6,549-50, 552-4. PubMed ID: 17096472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV pharmacogenomics: closer to personalized therapy?
    Payne DA; Bryant BJ;
    Am J Pharmacogenomics; 2004; 4(3):141-50. PubMed ID: 15174895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of antiretrovirals.
    Tozzi V
    Antiviral Res; 2010 Jan; 85(1):190-200. PubMed ID: 19744523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
    Nolan D; Gaudieri S; Mallal S
    J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and challenges of antiretroviral research and therapy.
    Esté JA; Cihlar T
    Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification.
    Keiser O; Fellay J; Opravil M; Hirsch HH; Hirschel B; Bernasconi E; Vernazza PL; Rickenbach M; Telenti A; Furrer H;
    Antivir Ther; 2007; 12(8):1157-64. PubMed ID: 18240856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics in HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nacher I; Rendón A; Soriano V
    AIDS Rev; 2005; 7(2):103-12. PubMed ID: 16092504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in adverse reactions to antiretroviral drugs.
    Ofotokun I; Pomeroy C
    Top HIV Med; 2003; 11(2):55-9. PubMed ID: 12717043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy: are we aware of adverse effects?
    Wig N
    J Assoc Physicians India; 2002 Sep; 50():1163-71. PubMed ID: 12516702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists.
    Berns JS; Kasbekar N
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):117-29. PubMed ID: 17699198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.